Glenmark USA launches epinephrine injection, targets $42.7m market

Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals, has announced the launch of its Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial. This product is bioequivalent and therapeutically equivalent to Epinephrine Injection USP from BPI Labs. The company anticipates 180 days of Competitive Generic Therapy (CGT) exclusivity. According to IQVIA data, the Epinephrine Injection USP market achieved approximately $42.7 million in annual sales as of December 2024. Glenmark aims to broaden its institutional channel portfolio with this launch. The Company's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions.